- ￥6768
- AntibodySystem
- 0.31-5 μg/mL
- 0.156 μg/ml
- KDD30801
- France
- 2025年07月16日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 库存：
999
- 供应商：
AntibodySystem
- 检测范围：
0.31-5 μg/mL
- 检测方法：
Colorimetric
- 应用：
ELISA
- 标记物：
HRP
- 样本：
Plasma, Serum
- 灵敏度：
0.156 μg/ml
- 规格：
96T
| 稳定性和存储 | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| 检测方法 | Colorimetric |
| 精准度 |
CV<20% |
| 样本类型 | Plasma, Serum |
| 实验类型 | Quantitative |
| 灵敏度 | 0.156 μg/ml |
| 检测范围 | 0.31-5 μg/mL |
| 回收率 | 80-120% |
| 背景 | Indatuximab ravtansine (BT062) is an antibody-drug conjugate (ADC) based on a murine/human chimeric form of B-B4 (CD138-specific antibody), which is covalently conjugated to the maytansinoid drug DM4 via a disulfide bond-based linker. Maytansinoids are structural analogs of the cytotoxic agent maytansine, which has been evaluated in phase I and phase II clinical trials. They exhibit anti-mitotic activity by inducing metaphase arrest of dividing cells, causing cell death. Upon internalization of indatuximab ravtansine by target tumor cells, lysosomal processing of the disulfide linker generates a lysine metabolite which is reduced and S-methylated producing the lipophilic and cytotoxic metabolite, S-methyl-DM4. The mechanism of action of indatuximab ravtansine resembles that of trastuzumab emtansine, an antibody-drug conjugate indicated for HER2-positive metastatic breast cancer which uses the HER2-targeting properties of trastuzumab to deliver the cytotoxic DM1 within the cell by means of a stable linker. The intracellular drug delivery to target tumor cells can improve the therapeutic index of the cytotoxic drug and minimize exposure of normal tissue. Indatuximab ravtansine has previously been shown in vivo in multiple myeloma mouse xenograft models to significantly inhibit tumor growth and prolong host survival without any toxicity signals. Based on these preclinical results, a phase I clinical trial of indatuximab ravtansine demonstrated the first signs of clinical activity in patients with relapsed or refractory multiple myeloma without any toxicity signals. Furthermore, preliminary data from a phase I/IIa study in relapsed or refractory multiple myeloma indicated that indatuximab ravtansine is well tolerated even in a multiple-dose schedule and provided further evidence of clinical activity. Indatuximab ravtansine is being investigated as part of a treatment for multiple myeloma. |
| 别名 | BT-062, nBT062-DM4, Indatuximab ravtansine(1238517-16-2) |
| 运输 | 2-8 ℃ |
| 备注 | For Research Use Only. |
AntibodySystem Laboratories SAS was created in 2019 in France as an independent brand, specializing in the research, development, and production of protein and antibody reagents for the life sciences. We are committed to providing high-quality protein and antibody products to life science researchers worldwide. Our offerings include a variety of antibodies and proteins, such as traditional polyclonal antibodies, housekeeping antibodies, tag antibodies, high-activity proteins, functional antibodies for in vivo studies, low-background flow cytometry antibodies, highly specific nanobodies, specialized small molecule antibodies, phospho-specific antibodies, DNA/RNA antibodies, and PEG antibodies—over ten product lines in total.
AntibodySystem products span research areas including 48 viruses, superbugs, parasites, cancer, Alzheimer's, Parkinson's, allergic and hypersensitivity reactions, immune suppression, and immune activation.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
